MedTech Dive - Latest News

Merit buys hemostatic device maker Biolife for $120M

Merit CEO Fred Lampropoulos said Biolife’s StatSeal and WoundSeal devices “address an estimated $350 million global market opportunity.”

May 21, 2025 - 16:50
 0
Merit buys hemostatic device maker Biolife for $120M

Merit CEO Fred Lampropoulos said Biolife’s StatSeal and WoundSeal devices “address an estimated $350 million global market opportunity.”

Read More

Tags:

Previous Article

Atomik AM eyes growth with £600k investment

Next Article

Virtuoso Surgical completes first bladder cancer removal cases with robotic system

Related Posts

Embecta restructures again, outlines tariff costs

Embecta restructures again, outlines tariff costs

May 13, 2025  0

AdvaMed CEO Scott Whitaker pleads for tariff relief in Senate hearing

AdvaMed CEO Scott Whitaker pleads for tariff relief in ...

May 14, 2025  0

Siemens Healthineers invests $150M in US, moves production from Mexico

Siemens Healthineers invests $150M in US, moves product...

May 16, 2025  0